David Mott has served on Ardelyx’s board of directors since March 2009 and has been the chairperson of the board of directors since March 2014. David is currently a private investor through Mott Family Capital.
From September 2008 to February 2020, David served as a general partner of New Enterprise Associates (NEA), an investment firm focused on venture capital and growth equity investments, where he led the healthcare investing practice.
Prior to joining NEA, David worked at MedImmune, a biotechnology company and subsidiary of AstraZeneca, and served in numerous roles during his tenure, including president and chief executive officer, chief financial officer, and president and chief operating officer. During that time, David also served as executive vice president of AstraZeneca, following AstraZeneca Plc’s acquisition of Medimmune in June 2007.
Earlier in his career, he was a vice president in the healthcare investment banking group at Smith Barney, Harris Upham & Co. Inc.
David serves as the chairperson of the board of directors for Adaptimmune, and Mersana Therapeutics, and serves on the board of directors of Novavax. Dave is also Chair of the Board for Adaptimmune and Mersana and is a member of the board for Novovax.
He earned a B.A. in Economics and Government from Dartmouth College.
What is David M. Mott's net worth?
The estimated net worth of David M. Mott is at least $9.64 million as of February 24th, 2025. Mr. Mott owns 2,015,494 shares of Ardelyx stock worth more than $9,642,123 as of April 1st. This net worth evaluation does not reflect any other investments that Mr. Mott may own. Learn More about David M. Mott's net worth.
How do I contact David M. Mott?
The corporate mailing address for Mr. Mott and other Ardelyx executives is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. Ardelyx can also be reached via phone at (510) 745-1700 and via email at investor@ardelyx.com. Learn More on David M. Mott's contact information.
Has David M. Mott been buying or selling shares of Ardelyx?
David M. Mott has not been actively trading shares of Ardelyx within the last three months. Most recently, on Monday, February 24th, David M. Mott bought 77,729 shares of Ardelyx stock. The stock was acquired at an average cost of $5.00 per share, with a total value of $388,645.00. Following the completion of the transaction, the director now directly owns 2,015,494 shares of the company's stock, valued at $10,077,470. Learn More on David M. Mott's trading history.
Who are Ardelyx's active insiders?
Are insiders buying or selling shares of Ardelyx?
In the last year, Ardelyx insiders bought shares 3 times. They purchased a total of 490,029 shares worth more than $2,377,766.00. In the last year, insiders at the biopharmaceutical company sold shares 40 times. They sold a total of 1,095,031 shares worth more than $7,315,583.30. The most recent insider tranaction occured on March, 7th when CEO Michael Raab sold 41,668 shares worth more than $223,340.48. Insiders at Ardelyx own 5.9% of the company.
Learn More about insider trades at Ardelyx. Information on this page was last updated on 3/7/2025.
